Skip to main content

Blocking the PI3K/PKB Pathway in Tumor Cells

Buy Article:

Your trusted access to this article has expired.

$68.00 + tax (Refund Policy)

A substantial number of experimental and epidemiological studies support an important role for the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) pathway in the biology of human cancers. Components of this signaling cascade have been found to be deregulated in a wide range of solid tumors and hematologic malignancies, and extensive anti-cancer therapeutic programs are now devoted to the identification of agents that specifically block this molecular pathway.

This article focuses on the current knowledge of the alterations of the PI3K/PKB pathway in cancer cells and ongoing drug discovery efforts to therapeutically target it. Particular emphasis is placed on medicinal chemistry activities to identify and develop compounds able to modulate the kinase activity of its main molecular components.

Keywords: apoptosis; cell survival; experimental therapeutics; kinase inhibitors; lipid kinase; serine/threonine kinase; targeted therapy

Document Type: Review Article

Affiliations: Novartis Institutes for Bio-Medical Research, WKL-136.4.84, CH-4002, Basel, Switzerland.

Publication date: September 1, 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content